Tadeusz Robak, MD, PhD

home / authors / tadeusz-robak-md-phd

Articles

Tadeusz Robak, MD, PhD

Dr. Roback on Subsequent Treatment Following Ibrutinib Discontinuation in CLL

Tadeusz Robak, MD, PhD
October 27th 2021

Tadeusz Robak, MD, PhD, discusses subsequent treatment after discontinuation of ibrutinib on the phase 3 RESONATE-2 trial in patients with chronic lymphocytic leukemia.

Read More

Tadeusz Robak, MD, PhD

Dr. Robak on the Inclusion Criteria of the RESONATE-2 Trial in CLL

Tadeusz Robak, MD, PhD
October 25th 2021

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Read More

Tadeusz Robak, MD, PhD

Dr. Robak on the Results of the 7-Year Follow-Up of RESONATE-2 in CLL

Tadeusz Robak, MD, PhD
September 21st 2021

Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data